Summary Safety Review - MELATONIN (N-acetyl-5-methoxytryptamine) - Review of the Safety of Melatonin in Children and Adolescents

After becoming aware of international reports about neurological side effects, such as anxiety, panic reaction, visual hallucinations and seizures, possibly associated with melatonin use in children and adolescents ranging from newborn to 18 years old (pediatric population), Health Canada did a review of this safety issue in this age group.

Données et ressources

Info additionnelle

Champ Valeur
Dernière modification avril 17, 2026, 17:34 (TU)
Créé le avril 17, 2026, 17:34 (TU)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2020-12-07 00:00:00
open_canada_keywords {"fr": ["Examen sommaire de l'innocuité", "Loratadine", "rythme cardiaque anormal", "allongement de l'intervalle QT", "utilisation de produits médicamenteux en vente libre"], "en": ["Summary Safety Review", "MELATONIN", "N-acetyl-5-methoxytryptamine", "review of safety", "Melatonin-use in Children-and-Adolescents", "neurological side effects", "anxiety", "panic reaction", "visual hallucinations", "seizures"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Résumé de l'examen de l'innocuité - MÉLATONINE (N-acétyl-5-méthoxytryptamine) - Examen de l'innocuité de la mélatonine chez les enfants et les adolescents
update_frequency as_needed